Weight Loss Drugs Explained: Ozempic, Wegovy, Mounjaro and the NHS

In the space of about three years, a class of medicines originally designed for type 2 diabetes has rewritten how Britain talks about weight. Research from University College London estimates that around 1.6 million adults in England, Wales and Scotland used a weight-loss jab in the year to early 2025 — most of them paying privately, many buying online, and a striking number unsure exactly what they were taking or how it differed from the version their neighbour was on.

That confusion is understandable, because the marketing is relentless and the names are a mess. Ozempic, Wegovy and Mounjaro get used almost interchangeably in conversation, yet they are not the same thing, are not licensed for the same purpose, and do not produce the same results. This guide cuts through it. I spend most of my working life translating clinical evidence into plain English, and what follows is the independent version — what these drugs are, how well they actually work according to the trial data rather than the testimonials, who can get them on the NHS and who has to pay, what they cost, the risks that matter, what happens when you stop, and how to avoid the genuinely dangerous corners of this market. No discount codes, no affiliate links, no “before and after” — just the evidence as it stands in 2026.

What these drugs actually are, and how they work

The weight-loss injections dominating the conversation belong to a family of medicines that mimic gut hormones your body releases after eating. The original class is the GLP-1 receptor agonists — GLP-1 standing for glucagon-like peptide-1, a hormone that signals fullness to the brain, slows how quickly the stomach empties, and helps regulate blood sugar. Semaglutide (sold as Ozempic and Wegovy) and liraglutide (Saxenda) work this way. The newest drug, tirzepatide (Mounjaro), goes a step further: it is a dual agonist, activating both the GLP-1 receptor and a second gut hormone receptor called GIP, which appears to give it an edge on appetite and metabolism.

The practical effect is the same story told at different volumes. You feel full sooner, stay full longer, think about food less, and as a result eat less without the relentless hunger that sabotages most diets. None of this is magic or, despite the framing of countless social media posts, a shortcut that bypasses biology. These drugs change appetite signalling; the weight loss follows from eating less over many months. That distinction matters for everything that comes later in this guide, particularly the question of what happens when you stop.

Their arrival as weight-loss treatments was partly accidental. They were developed for type 2 diabetes — semaglutide as Ozempic, tirzepatide as Mounjaro — and during diabetes trials researchers noticed participants were losing substantial amounts of weight. Higher-dose versions were then licensed specifically for weight management: semaglutide became Wegovy, and tirzepatide gained a weight-management licence alongside its diabetes one.

More than appetite: the wider effects

One of the most consistent things people report is harder to capture on a set of scales: the quietening of what many call “food noise” — the near-constant background chatter about what and when to eat next, the snack you keep thinking about, the second helping you talk yourself into. For people who have spent years feeling at war with their own appetite, that change can be the most psychologically significant part of treatment, and it helps explain why these drugs succeed where willpower-based dieting so often fails. They are not making people more disciplined; they are turning down a biological signal that discipline was always fighting uphill against.

The effects also reach beyond the waistline. Because these are fundamentally metabolic medicines, the weight loss tends to drag a cluster of related markers in the right direction — blood sugar, blood pressure and cholesterol often improve, and there is growing evidence of benefit in conditions linked to excess weight, from obstructive sleep apnoea to fatty liver disease, and increasingly for the metabolic features of PCOS. That is part of why clinicians increasingly think of them as treatments for metabolic health rather than slimming aids, and why the NHS prioritises people whose weight is already damaging other parts of their health.

The main medicines, side by side

Here is how the options on the UK market compare. The two injectable GLP-1/GIP drugs dominate, but it is worth knowing the older treatments still exist.

Drug (active ingredient)	Brand	Type	Licensed for	How taken
Tirzepatide	Mounjaro	Dual GIP/GLP-1 agonist	Weight management and type 2 diabetes	Weekly injection
Semaglutide	Wegovy	GLP-1 agonist	Weight management (and cardiovascular risk)	Weekly injection (oral version newly approved)
Semaglutide	Ozempic	GLP-1 agonist	Type 2 diabetes only	Weekly injection
Liraglutide	Saxenda	GLP-1 agonist	Weight management	Daily injection
Orlistat	Xenical / Alli	Lipase inhibitor	Weight management	Capsule with meals

Ozempic and Wegovy are the same drug — so why the different names?

This is the single most common point of confusion, so it is worth stating plainly: Ozempic and Wegovy contain the identical active ingredient, semaglutide. The difference is the licence and the dose. Ozempic is licensed in the UK only for type 2 diabetes; Wegovy is the same molecule licensed at higher weight-management doses for obesity. Because Ozempic became famous first, its name stuck as shorthand for the whole category — but you cannot get Ozempic on the NHS for weight loss, and a responsible prescriber will not supply it off-label as a slimming aid. When people say they are “on Ozempic” to lose weight, they are usually either taking Wegovy, taking Mounjaro, or have been sold something off-licence. Getting the names right is the first step to understanding what you are actually being offered.

How well do they actually work?

Very well, by the standards of anything that came before — but with a clear hierarchy, and with a gap between the headline averages and what any individual can expect. The trial evidence is now genuinely strong, including, as of 2025, the first large head-to-head comparison of the two leading drugs.

In the landmark STEP 1 trial, adults taking weekly semaglutide lost an average of 14.9% of their body weight over 68 weeks, against just 2.4% on placebo. Tirzepatide raised the ceiling: in SURMOUNT-1, participants on the highest dose lost an average of 20.9% over 72 weeks. For years those were separate trials with different participants, so comparisons were inexact. That changed with SURMOUNT-5, published in the New England Journal of Medicine in 2025 — the first trial to put the two drugs head to head.

Trial	Drug	Average weight loss	Duration
STEP 1	Semaglutide (Wegovy)	14.9%	68 weeks
SURMOUNT-1	Tirzepatide (Mounjaro)	20.9%	72 weeks
SURMOUNT-5 (head-to-head)	Tirzepatide	20.2%	72 weeks
SURMOUNT-5 (head-to-head)	Semaglutide	13.7%	72 weeks

In SURMOUNT-5, 751 adults with obesity were randomly assigned to one drug or the other for 72 weeks. Those on tirzepatide lost 20.2% of their body weight on average — about 22.8kg — compared with 13.7%, or 15.0kg, on semaglutide. Nearly a third of the tirzepatide group lost at least a quarter of their body weight, roughly double the proportion on semaglutide. On raw weight loss, the dual-agonist drug is clearly the more powerful of the two.

Two caveats matter enormously, though. First, these are averages, and individual response varies widely; some people lose far less, a minority barely respond, and tolerance of side effects affects how high a dose anyone can reach. Researchers also noted that men tended to lose around 6% less than women on both drugs. Second, weight loss is not the only outcome that counts. Semaglutide has the stronger evidence for protecting the heart: the SELECT trial showed it cut the risk of major cardiovascular events such as heart attack and stroke by around 20% in people with existing cardiovascular disease and excess weight — which is why Wegovy, uniquely, carries a licence for cardiovascular risk reduction. The “best” drug depends on what you are actually trying to achieve, and that is a conversation for a prescriber, not a price-comparison site.

Why your own results may differ

It is worth dwelling on those averages, because the gap between the trial headline and the bathroom scale is where a lot of disappointment lives. A 20% average means some people lose 30% and others lose 5%, and a small minority — perhaps one in ten — barely respond at all. Genetics, starting weight, diet, activity, sleep, and how high a dose you can tolerate without intolerable nausea all feed into where you land.

The dose itself is part of the story. Both drugs are deliberately started at a low dose and stepped up roughly every four weeks, partly to limit side effects and partly because the bigger results come at the higher strengths. Someone who cannot tolerate the climb, or who stops at a lower dose, will usually see less weight loss than the trial figures suggest. Most people also hit a plateau after several months, as the body adapts and a new equilibrium settles in; this is normal and not a sign of failure, though it is often the point at which motivation and habits are tested. The NHS encodes a version of this reality in its rule that treatment only continues past six months if you have lost at least 5% of your starting weight — a recognition that the drugs do not work equally well for everyone, and that there is little sense in continuing an expensive medication that is not delivering.

Can you get these drugs on the NHS?

Sometimes, but the criteria are strict, the rollout is deliberately slow, and “available on the NHS” turns out to be one of the most misleading phrases in this whole story. Both Wegovy and Mounjaro are approved by NICE for NHS weight management, but approval is not the same as access — and what you qualify for depends heavily on your BMI, your other health conditions, and where you live.

Wegovy on the NHS

Semaglutide (Wegovy) was recommended by NICE in 2023 for use within specialist weight management services — the NHS “Tier 3” clinics, staffed by dietitians, psychologists and doctors. To be eligible you generally need a BMI of at least 35 (or 32.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, who face higher risk at lower BMIs) plus at least one weight-related health condition. Treatment is time-limited — typically up to two years — and you must access it through a referral to a specialist service, not a standard GP prescription. In practice, supply constraints and limited clinic capacity have meant long waits and patchy availability.

Mounjaro on the NHS, and the twelve-year rollout

Tirzepatide (Mounjaro) is the bigger story, because NICE recommended it for far more people — an estimated 3.4 million eligible adults in England. Faced with that number, NHS England chose a phased rollout expected to take around twelve years, with roughly 220,000 of the highest-need patients reached in the first three years. The reasoning is bluntly practical: if Mounjaro were offered to everyone eligible at once, it has been estimated it could consume up to a fifth of all GP appointments.

The timeline has moved in stages. From March 2025, Mounjaro for weight loss was available only through specialist weight management services. From June 2025, some areas began funding it through primary care under interim guidance. And from April 2026, prescribing for obesity was folded into the GP contract through new Quality and Outcomes Framework indicators — though, crucially, individual GP practices are not obliged to take part, so availability still varies by surgery and by region.

In the first phase, the bar is high. The earliest eligible group are adults with a BMI of 40 or more (adjusted down by 2.5 for the ethnic groups noted above) and four out of five weight-related conditions: type 2 diabetes, high blood pressure, cardiovascular disease, high cholesterol, and obstructive sleep apnoea. Later cohorts, with lower thresholds, are scheduled to open gradually over the rollout. Whichever drug you are prescribed, the NHS applies a checkpoint: treatment continues past six months only if you have lost at least 5% of your starting weight.

The reality check

It is worth being honest about what all this means on the ground. You cannot simply ask your GP for a weight-loss jab because you would like to lose a stone. NHS access is built around clinical need, local commissioning and a queue — not demand. You may meet NICE’s criteria on paper and still not be offered the drug yet in your area, because your integrated care board is working through higher-priority patients first. The medication also comes wrapped in what the NHS calls “wraparound care” — dietary and activity support — because it is treated as one part of a managed weight-loss programme, not a product handed over at a counter. For the large majority of people who want these drugs, the NHS is currently not the route, which is exactly why the private market has exploded.

What about Scotland, Wales and Northern Ireland?

Everything above describes England, because NICE and NHS England decisions apply only there. The other UK nations run their own systems, and the picture differs in the detail even though the broad story — approved in principle, rationed in practice — is much the same. Scotland has its own appraisal body, the Scottish Medicines Consortium, and Wales the All Wales Medicines Strategy Group; both have accepted these drugs for NHS use, but each nation has built its own phased, capacity-limited pathway through specialist weight management services, so eligibility thresholds and waiting times vary by nation and by health board. Northern Ireland makes its own arrangements again.

Two practical differences are worth holding on to. First, prescription charges: medicines are free in Scotland, Wales and Northern Ireland, whereas in England you pay the standard charge per item, so the cost calculus of an NHS prescription differs across the border. Second, the private market is effectively identical UK-wide — the same regulated online pharmacies serve all four nations under the same MHRA and GPhC rules — so wherever you live, the option to pay privately looks broadly the same even when NHS access does not. If you are outside England, the most reliable move is to check your own health board’s current weight management pathway rather than assume the English timeline applies.

Going private: what it really costs

If you do not meet the NHS criteria or cannot wait, the private route is open, faster and considerably cheaper than most people assume — but the pricing is a minefield of hidden fees, and a major price rise in 2025 reshaped the market. Private providers apply looser clinical thresholds than the NHS: typically a BMI of 30 or more, or 27 or more with a weight-related condition.

As a rough guide to mid-2026 pricing across regulated UK pharmacies, Wegovy starts at around £99 a month at the lowest starter dose and Mounjaro from roughly £130, with both rising as the dose escalates — Mounjaro can reach £250 to £350 a month at higher maintenance strengths. After Eli Lilly raised its wholesale Mounjaro prices in September 2025, monthly costs jumped and now vary widely between pharmacies, which is why the same medication can differ by hundreds of pounds a year depending on where you buy it.

Cost element	Typical 2026 figure	Notes
Starter dose (monthly)	£99–£150	Lowest doses; not a long-term maintenance dose
Maintenance dose (monthly)	£200–£350	Higher strengths cost more; Mounjaro at the top end
Consultation fee	£0–£50	Some providers include it, others charge separately
Delivery (cold-chain)	£0–£8	Must be kept refrigerated, 2–8°C
Indicative annual cost	~£1,500–£4,000	Depends on drug, dose and provider

The headline price is rarely the real price. Some pharmacies advertise a low pen cost and then add separate fees for the consultation, needles, a sharps bin and delivery; others bundle everything. A pen at £120 plus £25 consultation, £8 needles and £6 delivery is dearer than an all-inclusive £149. The practical advice is simple: always ask for the total monthly cost with everything included, and because private prescriptions are not tied to one pharmacy, you can switch providers if a better price appears. One newer development worth noting is the arrival of an oral version of semaglutide — a Wegovy pill — approved by the MHRA in mid-2026 and priced comparably to the injection, which may suit people who would rather not inject.

Mounjaro or Wegovy: which is right for you?

If you have a genuine choice — which, privately, most people do — the honest answer is that it depends on what you are optimising for, not simply on which drug loses the most weight. Mounjaro wins on raw weight loss and Wegovy wins on proven heart protection, and for many people cost and tolerability matter more than either. The table below frames the trade-offs the way a good prescriber would.

Consideration	Mounjaro (tirzepatide)	Wegovy (semaglutide)
Average weight loss	Higher (~20%)	Lower (~14–15%)
Proven heart protection	Trials ongoing	Yes — licensed for it
Mechanism	Dual GIP/GLP-1	GLP-1 only
Oral option	Injection only	Pill now available
Typical private cost	Often higher post-2025	Often the cheaper starter

In practice, the reasoning tends to go like this. If your main goal is the greatest possible weight loss and you tolerate the drug well, tirzepatide is the stronger performer. If you have established cardiovascular disease, semaglutide’s licensed heart-protection benefit may tip the balance, and it is a decision that genuinely belongs with a doctor. If cost is the deciding factor, Wegovy’s lower starter price or the new pill may make more sense. And if you simply cannot face a weekly injection, the oral version of semaglutide changes the maths entirely. There is no universally “best” drug — only the best fit for your goals, your health and your budget, which is exactly why these should be prescribed after a real conversation rather than picked from a menu.

What to expect in the first few months

The realistic arc of treatment is slower and less dramatic than the transformation videos suggest, and knowing the shape of it in advance prevents a lot of unnecessary worry. You do not start on the dose that produces the headline results. Both drugs begin at a low introductory dose and step up gradually, usually about every four weeks, so your body — and particularly your gut — has time to adjust. Pushing the dose up too fast is the main cause of the worst side effects.

In the first few weeks, most people notice the appetite change before they notice the scales: meals feel satisfying sooner, cravings soften, and the “food noise” quietens. Visible weight loss typically becomes clear over the following months rather than days, and it is rarely linear — there are good weeks and stalled ones. Somewhere after the first several months many people reach a plateau as the body adapts, which is normal and not a failure of the drug. Throughout, the unglamorous fundamentals do a lot of the heavy lifting: eating enough protein and doing some resistance exercise to protect muscle, since a portion of the weight lost on these drugs is muscle rather than fat, and keeping the lifestyle changes going so that progress holds.

You should also expect oversight, not just a monthly delivery. A responsible service — NHS or private — reviews how you are responding, checks tolerability, and adjusts the plan, with the NHS formally reassessing at six months against that 5% threshold. If a provider is content to keep posting you higher and higher doses with no check-ins, that is a warning sign about the quality of care, not a convenience.

The risks and side effects you need to know

These are genuinely effective medicines, but they are not consequence-free, and the honest picture sits somewhere between the breezy reassurance of sales pages and the alarmism of tabloid headlines. The overwhelming majority of side effects are gastrointestinal and manageable; a small number are serious and worth taking seriously.

By far the most common effects are nausea, vomiting, diarrhoea and constipation, which is why both drugs are started low and increased slowly — the gradual “titration” is designed to let your gut adjust. These symptoms are usually worst during dose increases and settle at a stable dose. Gastrointestinal complaints make up roughly half of all the side effects reported to the UK regulator for these drugs. Other recognised issues include gallstones (rapid weight loss raises the risk), and loss of muscle as well as fat, which is why protein intake and resistance exercise matter during treatment. The much-discussed “Ozempic face” — a gaunt, hollowed look — is simply the visible result of fast facial-fat loss, not a distinct medical effect.

The risk that has prompted the most regulatory attention is acute pancreatitis. In January 2026 the MHRA issued a strengthened safety warning after reviewing reports of severe and, in rare cases, fatal pancreatitis. Between 2007 and October 2025 it had received 1,296 reports of pancreatitis linked to these drugs, of which 19 were fatal — set against an estimated 25.4 million packs dispensed over five years, which puts the rarity in perspective without dismissing the seriousness. The regulator’s advice is clear: anyone taking these medicines should seek urgent medical help for severe, persistent stomach pain that may spread to the back, often with nausea and vomiting, as it can signal pancreatitis. If pancreatitis is confirmed, the drug should be stopped and not restarted. The MHRA, working with Genomics England through its Yellow Card Biobank, is now investigating whether genetics make some people more vulnerable.

A few other points are easy to miss but important. These drugs can reduce how well the contraceptive pill is absorbed, so an additional method such as condoms is advised — there have already been so-called “Ozempic babies” from unplanned pregnancies. They must not be used in pregnancy or while breastfeeding. They are not suitable for people with a personal or family history of medullary thyroid cancer or the syndrome MEN 2, or for those with a history of pancreatitis. You should tell an anaesthetist before any surgery, because slowed stomach emptying affects sedation safety. One reassuring note amid the warnings: after an earlier scare, the MHRA reviewed the evidence in 2024 and concluded the data did not support a causal link between these drugs and depression or suicidal thoughts. Whatever you are taking, suspected side effects can and should be reported through the MHRA’s Yellow Card scheme — the system that surfaced the pancreatitis signal in the first place.

How to manage the common side effects

Because the gastrointestinal effects are so common, it is worth knowing the practical steps that reduce them — most are about working with the way the drug slows digestion rather than against it. Eating smaller portions, more slowly, and stopping at the first sign of fullness helps a great deal, since the medication is already telling your stomach to empty more slowly and large or rich meals sit heavily. Many people find that fatty, fried and very sweet foods trigger the worst nausea, while bland, lower-fat meals are easier to tolerate, especially in the days after a dose increase. Staying well hydrated matters more than usual, partly because reduced eating and occasional vomiting can tip people into dehydration, and constipation responds to the familiar combination of fluids, fibre and movement.

The single most effective lever, though, is the dose schedule. Side effects cluster around dose increases and then ease, so if a step up is rough, a prescriber can hold you at the current dose for longer before climbing again rather than forcing the pace. A GP or prescriber can also suggest anti-sickness measures where appropriate. What you should not do is quietly endure symptoms that feel out of proportion: severe or persistent abdominal pain, especially radiating to the back, signs of dehydration, or any reaction that frightens you all warrant prompt medical contact rather than toughing it out. Effective management is the difference between a tolerable adjustment period and giving up on a treatment that might have worked.

What happens when you stop?

Most people regain much of the weight — and this is the fact the marketing is quietest about. These drugs treat appetite while you take them; they do not permanently reset it. When the medication stops, the hunger signals return, and for many people so does the weight.

The evidence here is unambiguous. In the extension of the STEP 1 trial, participants who had lost an average of 17.3% of their body weight on semaglutide regained roughly two-thirds of it within a year of stopping the drug and the accompanying lifestyle support, ending up with a net loss of about 5.6%. The cardiometabolic improvements — better blood pressure, blood sugar and cholesterol — largely reversed too. The picture was similar for tirzepatide: in the SURMOUNT-4 trial, people who switched to placebo after the initial phase regained a substantial share of their lost weight, while those who stayed on the drug maintained or extended their results.

The honest implication is that, for many people, these are long-term treatments for a long-term condition, more like blood-pressure medication than a short course of antibiotics. That reframes the cost question considerably: a private prescription is not a one-off summer expense but a potentially open-ended one. It also raises the importance of everything the drug does not do on its own. Building genuine habit change — sustainable eating patterns, strength training to protect muscle, better sleep — while appetite is suppressed gives you the best chance of holding on to results, whether you eventually stop or move to a lower maintenance dose under medical guidance. Real-world weight regain tends to be gentler than the trial figures, partly because people in everyday life rarely stop as abruptly as a trial protocol demands.

This has changed how some clinicians think about the end of treatment. Rather than a hard stop, the emerging approach is a managed “off-ramp”: tapering to the lowest dose that still holds the weight, or planning a long-term low-dose maintenance phase, much as you would not abruptly abandon medication for any other chronic condition. None of that is a reason to avoid these drugs — but it is a reason to go in with eyes open about the likely length of the commitment, and to use the window of suppressed appetite to build the habits that will carry whatever the drug cannot.

Buying safely: counterfeits, dodgy prescribers and the law

The single most important safety rule is this: only ever obtain these medicines through a properly regulated UK pharmacy with a genuine clinical assessment, because the alternative market is dangerous and, in 2025, increasingly criminal. As demand has outstripped legitimate access, a black market in counterfeit and illegally supplied weight-loss jabs has grown alongside it, and the MHRA seized large quantities of illegal weight-loss medicines during 2025, some linked to serious harm. Fake pens may contain the wrong dose, the wrong drug, or no active ingredient at all — and they come with none of the clinical oversight that makes these treatments reasonably safe.

The rules around how these drugs can be sold and advertised also tightened sharply. In the UK it is illegal to advertise prescription-only medicines to the public, and in 2025 the regulators acted on it: the General Pharmaceutical Council, the MHRA and the Advertising Standards Authority jointly clarified that adverts naming weight-loss jabs — or even using terms like “weight-loss injection”, “GLP-1” or images of injection pens — are not allowed. The ASA identified around 900 rule-breaking ads in a single year, and banned influencer posts that promoted brands like Wegovy and Mounjaro through discount codes and referral links. Separately, from early 2025 the GPhC required online prescribers to independently verify a patient’s weight and BMI rather than relying on a self-reported questionnaire or a photo — a direct response to services that were handing out powerful medication after the most cursory of checks.

For anyone buying privately, that translates into a short checklist. Use a pharmacy registered with the GPhC — you can search the register directly. Make sure a named, UK-registered prescriber reviews your actual medical history, not just a tick-box form. Be deeply suspicious of any seller offering these drugs without a proper consultation, at implausibly low prices, or through social media. And check that the medicine arrives in proper temperature-controlled packaging, because these injections must be kept refrigerated. If an offer feels more like buying trainers than obtaining a prescription medicine, walk away.

Who are they actually for — and who should think twice?

These drugs are designed for people whose weight is genuinely harming their health, not as a cosmetic quick fix for the last few pounds before a holiday — and the distinction is both medical and ethical. The clinical evidence, and every NHS and NICE criterion, frames them as treatments for obesity and serious overweight, usually alongside a related health condition. Used that way, in people with a high BMI and conditions like type 2 diabetes or high blood pressure, the benefits clearly outweigh the risks for most.

It helps to start from the right framing. Obesity is now widely recognised in medicine as a chronic, relapsing condition driven by biology, environment and genetics — not a simple failure of willpower — and that is precisely why a drug that acts on appetite biology works where decades of “eat less, move more” advice did not. Treating it as a moral issue rather than a medical one is part of why so many people spent years blaming themselves. At the same time, there is an uncomfortable equity dimension worth naming: with NHS access rationed to the highest-need patients and a phased rollout stretching over a decade, the fastest route to these drugs is currently the ability to pay several hundred pounds a month privately. That risks a two-tier system in which the people who can afford treatment get it now and those who cannot wait in a queue — a fairness question the rollout has not yet resolved.

The picture is murkier for people chasing modest weight loss from a near-healthy starting point, where the risk-benefit balance shifts and the open-ended cost and commitment look much less reasonable. There are also groups for whom these drugs are not appropriate at all: anyone pregnant, trying to conceive or breastfeeding; people with a history of pancreatitis or of medullary thyroid cancer or MEN 2; and — a point that deserves more attention than it gets — people with a history of eating disorders, for whom an appetite-suppressing drug can be genuinely hazardous and should only ever be considered with specialist input.

It is also worth holding on to some perspective the marketing strips away. These medicines work best as part of a broader change, not instead of one. The NHS wraps them in dietary and activity support for a reason, and the people who do best tend to treat the drug as a powerful tool that makes lasting change possible rather than as the change itself. As I see it, the most useful question is not “can I get it?” but “what am I trying to treat, for how long, and at what cost?” If you can answer that clearly with a clinician you trust, you are in a far better position than most of the 1.6 million people who started these drugs last year.

What’s next: the pipeline

The current drugs are not the end of the story — the pace of development in this field is extraordinary, and the next few years will bring both more options and, probably, more competition on price. The most immediate change is the arrival of pills. An oral version of semaglutide — effectively a Wegovy tablet — gained MHRA approval in mid-2026, offering the same active ingredient without the injection, which is likely to widen access for the needle-averse even if early pricing is similar to the jab.

Beyond that, a wave of next-generation treatments is moving through late-stage trials, including further oral drugs and “triple agonists” that target a third gut hormone in pursuit of even greater weight loss. None of these should be bought ahead of approval, and the usual rule applies doubly to anything described as “new” online — if it is not yet licensed and dispensed through a regulated pharmacy, it is not safe to take. What does seem certain is that the NHS will keep expanding access to the established drugs over the coming decade, and that the gap between what these medicines can do and who can actually get them — the defining tension of this whole subject — will be with us for some time yet. For the latest developments as they are approved, our treatment and research coverage tracks each new decision.